← Back to Company DatabaseVisit Website
Thrive Earlier Detection
Blood test for multi-cancer early detection, now part of Exact Sciences.
AcquiredCambridge, MAFounded 2019
About
Thrive Earlier Detection developed CancerSEEK, a blood test capable of detecting multiple cancer types by analyzing circulating tumor DNA and proteins. The technology was born out of pioneering research at Johns Hopkins University. Thrive was acquired by Exact Sciences in 2021 for approximately $2.15 billion.
Total Funding
$257MKey Product
CancerSEEK multi-cancer blood testGeography
North AmericaKey Investors
Third Rock VenturesCasdin CapitalSection 32
Focus Areas
Early Detection / ScreeningDiagnostics
Technology
Liquid BiopsyGenomics / Sequencing
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026